AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04960735 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VOICE intervention
Description: The intervention consists of four stages:~* S1, Value identification and description of current care processes: Needs are detected from two perspectives: feedback from patients and mapping of healthcare processes. ICHOM questionnaires are reviewed. Patient surveys and clinical forms are developed. The methodology for cost analysis is set up.~* S2, Intervention implementation: Patients are recruited according to the eligibility criteria. Their care follows the current healthcare pathway and information is collected at different time points.~* S3, Assessment of outcomes and continued benchmarking: Data and costs are analysed at both local level and Community level (benchmarking). Interviews and focus groups are held (optional). Root cause analysis is performed.~* S4, Model construction: Based on the process mapping and on root cause analysis, the multidisciplinary team designs the new care pathway. Professionals are trained in those tasks allocated according to the new care process.
Study NCT02874274 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Study NCT02874274 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home Visit Program (HVP)
Description: The study team will also contact the subject by phone within one week of each vaccination visit to assess for any adverse effects related to vaccination, included but not limited to: injection site pain, tenderness, swelling, pruritus, induration, or erythema; systemic symptoms such as fatigue, chills, headache, anorexia, malaise, myalgias, or anaphylaxis. Subjects will be contacted 90 days (+ 14 days) following Visit 3 to inquire about any additional symptoms and healthcare utilization.
Study NCT01745848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Study NCT03226275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol-Amlodipine FDC
Description: Participants received a single oral dose of 5 milligram(mg)/5 mg bisoprolol-amlodipine FDC tablet (Concor AM®) either on Day 1 or Day 15 under fasting or fed conditions.
Study NCT00478543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Study NCT03520855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serious game
Description: DIVE software will be accessible via internet, children and parents will have to their disposition a room at the hospital specifically to work on the software. The DIVE software is organized in chapters, each matches an item of the therapeutic education process and ends with a knowledge assessment. The child has to end every chapter and succeed every evaluation to pursue on the next chapter. Measures will be taken in order to avoid contamination bias between groups. Children will have to connect to DIVE 2 times per week for a time duration of at last 1 hour.
Study NCT03520855 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ETP
Description: Initial therapeutic education only will be applied in this group, with the help of doctors and nurses, based on theoretical educational lessons, reported on the AJD book.~Health education sessions will also be taught by nurses.
Study NCT03520855 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ETP
Description: Initial therapeutic education only will be applied in this group, with the help of doctors and nurses, based on theoretical educational lessons, reported on the AJD book.~Health education sessions will also be taught by nurses.
Study NCT03898739 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cervical Traction from different angles
Description: Intermittent traction will be applied, maximum force will be 16 kg, minimum force will be 12 kg, traction cycle of each minute consists of 20 seconds static traction at the maximum force then released down to the minimum force for 20 seconds then repeated for 20 seconds static traction. Traction session time will be 15 minutes, and the traction force will be increased progressively with speed (50%) of increment of force
Study NCT03833505 — intervention group
Intervention type: OTHER
Intervention: Bitestrip
Description: The parents of the patients were asked to complete a survey that included questions about the demographic data, medical history of the patient, clinical findings of E. For diagnosis of sleep bruxism, a single-use BiteStrip® device (Up2dent, Inc.), including an electromyographic electrode, small display screen and lithium cell, was used to record the increased electromyographic activity of the masticatory muscles during sleep and bruxism, other harmful oral habits, family life and habits.
Study NCT03226275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Description: Participants received 5 mg bisoprolol tablet as a single oral dose either on Day 1 or Day 15 under fasting or fed conditions.
Study NCT03226275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Participants received 5 mg amlodipine tablet as a single oral dose either on Day 1 or Day 15 under fasting or fed conditions.
Study NCT03991104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin (3 levels for phase I: 110 mg/m², 120 mg/m² and 130 mg/m²) is administered as a 2 h intravenous infusion in 500 mL of 5% glucose on day 1 and day 29 during the treatment course.
Study NCT03991104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 capsule
Description: Patients received a fixed dose of S-1 with a dose of 80 mg/m2/d twice daily for 2 weeks, every 4 weeks.
Study NCT03991104 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiotherapy (IMRT)
Description: The total radiation dose was set to 50.4 Gy, which was given in 28 fractions of 1.8 Gy once-daily fractions for over 5 weeks.
Study NCT02027623 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor skill training
Description: The participant will assist in selecting both simple and complex functional activities to practice. Difficulty will be graded to match the participant's motor capabilities. Three activities will be practiced per session. Within the practice of activities the training will emphasize 1) contraction of groups of specific trunk muscles, 2) earlier and greater movement of the hip, knee, and/or thoracic spine relative to the lumbar spine, 3) later and less movement of the lumbar spine relative to other regions. Within each activity the conditions of practice will vary based on 1) the participant's ability to perform the activity, and 2) the level of challenge the participant is faced with when performing the activity during his day. Equipment will be provided as needed.
Study NCT02027623 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Strength and flexibility exercise
Description: Exercises based on best evidence for effectiveness in people with chronic low back pain will be prescribed. Strengthening exercises will target all trunk muscles. Flexibility exercises will target all trunk and hip motions. All exercises will be performed at the intensity appropriate for the person's musculoskeletal fitness level based on the American College of Sports Medicine guidelines. Difficulty level, frequency, and number of repetitions will be modified based on guidelines described in the literature. Equipment will be provided as needed.
Study NCT02303691 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification
Description: Excessive attention to threat is theorized to be a critical contributor to chronic anxiety symptoms and related negative health consequences. Attention Bias Modification, which directly targets this mechanism, is a highly cost-effective intervention with growing empirical support for its potential efficacy in clinically anxious populations.
Study NCT02303691 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Neutral Training
Description: A control version of computerized attention training.
Study NCT04432246 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous theta burst stimulation (cTBS)
Description: 50Hz of 90% MT for 3 pulses train over will be repeated at 200ms for the 40s, 600 pulses
Study NCT04553198 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Backward Locomotion Treadmill Training (BLTT)
Description: 9-training sessions of reverse treadmill training (no bodyweight support)over three weeks.
Study NCT04553198 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Backward Locomotion Treadmill Training (BLTT)
Description: 9-training sessions of reverse treadmill training (no bodyweight support)over three weeks.
Study NCT01014260 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is a randomized double-blind clinical trial of doxycycline 20 mg bid versus 100mg bid versus placebo, given for 3 months, to be conducted at a single center (JHH).
Study NCT01014260 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Doxycycline 20 mg bid versus Doxycycline 100 mg bid versus placebo
Study NCT00562211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LidoDyn
Description: Application of 2 gram of LidoDyn to the skin surface the patient's antecubital fossa 60 min prior to venipuncture
Study NCT00562211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMLA creme
Description: Application of 2 gram of EMLA creme to the skin surface the patient's antecubital fossa 60 min prior to venipuncture
Study NCT03143816 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Technosphere insulin
Description: This multi-center study will enroll 60 patients with T1D, A1c values between 6.5 to 10%. The patients will be randomized in 1:1 fashion to either TI or NL. Patients who are randomized into the NL arm will continue using their usual prandial insulin dose before meals. Patients who are randomized into the TI arm will be instructed to dose before the meals and take necessary corrections at 1- and 2-hours after meals to optimize PPBG (Table 1B). There will be a total of 7 study visits (screening visit, randomization visit, 2 clinic, and 3 phone visits). There will be a 4-week treatment comparison between TI and NL and 1-week of post-study follow up. (Phone visit; Figure-1). Standard lab tests (A1c, complete metabolic panel {CMP}, complete blood count {CBC}) will be performed at the screening visit.
Study NCT00511472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0941
Description: In Titration Scheme #1, MK-0941/matching placebo was initiated at 10-mg q.a.c. dose and increased on a daily basis (Titration Dose \[TD\] Days 1 to 4 of the Titration Phase 1) in 10-mg q.a.c. increments.~Titration Scheme #2 was a flexible-dose titration scheme in which MK-0941/matching placebo was given at a dose determined by a pre-prandial plasma glucose concentration for the subsequent meal on the previous day of administration on Days 1 to 4 of the Titration Phase 2.
Study NCT00511472 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 mg Placebo (Pbo), 20 mg Pbo, 30 mg Pbo or 40 mg Pbo q.a.c.
Study NCT00511472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LANTUS insulin
Description: LANTUS insulin dose will be similar to participant's previous dose of immediate or long-acting insulin
Study NCT00511472 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LANTUS insulin
Description: LANTUS insulin dose will be similar to participant's previous dose of immediate or long-acting insulin
Study NCT02687022 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peramis aberrometry
Description: A non-invasive photographic scan sequence acquired in under 10 seconds
Study NCT02687022 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iDesign aberrometry
Description: A non-invasive photographic scan sequence acquired in under 10 seconds
Study NCT03682549 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Oral microbiome analysis
Description: Oral swab from the buccal mucosa will be obtained and then analysed Oral Microbiome analysis:The microbial RNA will be sequenced using Next Generation Sequencer.
Study NCT02308020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally
Study NCT02146456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Study NCT01432717 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACE-536
Description: Subjects receive a total of 2 subcutaneous doses of ACE-536 on Day 1 and Day 15.
Study NCT01432717 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects receive a total of 2 subcutaneous doses of placebo on Day 1 and Day 15.
Study NCT04388774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: A single 40-minute intravenous infusion
Study NCT03027492 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gluten free diet
Description: The investigators will evaluate the modification of gynaecological disorder after a gluten (wheat)-free diet.
Study NCT01190982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEP-ETU
Description: 275 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, 6 Cycles or until progression or unacceptable toxicity develops.
Study NCT02483182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZEP-3 ointment 1.0%
Study NCT02483182 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acyclovir cream 5%
Study NCT04305080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anodic oxidation
Description: Abutments will undergo anodic oxidation process after etching with Hydrofluoric acid \& Nitric acid mixture for 10 minutes for debridement in a bath of distilled water with citric acid for 5 minutes to turn the abutment collar into pink color. The stainless steel plate will be connected to the cathode (-) and titanium abutments will be connected to the anode (+) end of the DC Power Supply. After then abutments will be left in distilled water for 10 minutes and sterilized before insertion in patient mouth.
Study NCT04305080 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Untreated abutment
Description: Abutment will be left untreated with its gray color.
Study NCT00343252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teriparatide
Description: 20 ug/day, subcutaneous, 18 months
Study NCT00343252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risedronate
Description: 35 mg/once weekly, oral, 18 months
Study NCT00343252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: once weekly, oral, 18 months
Study NCT00343252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: daily, subcutaneous, 18 months
Study NCT00947674 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellsorba EX
Description: conduct treatment twice a week for 3 weeks and once a week for 4 weeks, total 10 times
Study NCT00947674 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Cellsorba EX
Description: conduct treatment twice a week for 3 weeks and once a week for 4 weeks, total 10 times
Study NCT03313921 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Online Manifest Refraction
Description: The online manifest refraction is performed with a web-based application and consists of an assessment of visual acuity, an assessment of spherical refractive error, and an assessment of cylinder refractive error. The software is a class 1 CE-approved medical device.~The automated refraction is measured with a regular office-based autorefractor device; TOPCON RM-8000.
Study NCT02414581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chlorhexidine 0.12%/Ethyl alcohol 7%
Description: Mouth rinses with chlorhexidine 0.12%-based solution
Study NCT02414581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethyl Alcohol 7%
Description: Mouth rinses with Ethyl Alcohol 7%-based solution
Study NCT02414581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 2%/Ethyl alcohol 7%
Description: Mouth rinses with chlorhexidine 2%-based solution
Study NCT03742167 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: The mobile, HIPAA-compliant, video-conferencing platform, Zoom Pro, will be used on tablet computers as a low-cost telemedicine platform for the intervention group. This platform uses Wi-Fi or cellular data connection for video streaming. The investigators will use the telephone communication on this platform for control scenarios, to mimic the current standard for audio-only consultation. A web-based software platform (WireCast®) will capture video recordings over a secure wireless network.
Study NCT00988871 — intervention group
Intervention type: DEVICE
Intervention: PICC, CICC
Description: PICC insertion, CICC (advanced venous access with pulmonary artery catheter) insertion
Study NCT03905954 — intervention group
Intervention type: OTHER
Intervention: Usual care
Description: For this cross sectional survey, participants will be receiving usual care according to there health care systems
Study NCT02275494 — intervention group
Intervention type: PROCEDURE
Intervention: Total hip arthroplasty
Description: Cemented or uncemented total hip arthroplasty. No other intervention than observing patients operated according to routine practise at an orthopaedic department.
Study NCT01003990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir
Description: Tablets, Oral, 400 mg, once daily, indefinitely
Study NCT01003990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir/Ritonavir
Description: Tablets, Oral, 300/100 mg, once daily, indefinitely
Study NCT01003990 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir/Emtricitabine
Description: Tablets, Oral, 300/200 mg, once daily, indefinitely
Study NCT01003990 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/ritonavir
Description: Tablets, Oral, 400/100 mg, twice daily, indefinitely
Study NCT02178670 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSC-DC
Study NCT02178670 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: CSC-DC
Study NCT01492465 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 876
Description: Ascending single doses of study drug administered SC, with one cohort administered IV
Study NCT01492465 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AMG 876
Description: Ascending single doses of study drug administered SC, with one cohort administered IV
Study NCT01285271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon
Description: gaseous anesthetic, dosage: 50% (v/v) in 50% oxygen, continuous application before the start and after the end of extracorporal circulation
Study NCT01285271 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: inhalative anesthetic, dosage: 1.4% (v/v) in 50% oxygen/medical air , continuous application before the start and after the end of extracorporal circulation
Study NCT02919657 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Genepro Protein
Description: weekly blood draws to measure blood protein levels
Study NCT02919657 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey Protein
Description: weekly blood draws to measure blood protein levels
Study NCT04154176 — intervention group
Intervention type: OTHER
Intervention: CAM, Nu-DESC
Description: Two trained raters, who are blinded and have no access to each other's evaluation, administer the CAM and Nu-DESC questionnaires in each shift, during the first postoperative day after the discharge from the post-anaesthesia care unit, independently. The two assessments are completed within 60 minutes of each other. If the research team set the diagnosis of POD, the appropriate treatment will be initiated, according to the Hospital's protocol
Study NCT04470466 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: short pulse and Q-switched ND-YAG laser with topical carbon
Description: application of topical carbon cream, followed by two passes of short pulse 1064 ND-YAG, then one pass of Q-switched 1064 ND-YAG on one side of the face
Study NCT04470466 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fractional CO2 laser
Description: single pass of fractional CO2 laser on the other side of the face
Study NCT03286322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manuel therapy cervical spine
Description: the manuel therapy in physiotherapy is focused on the cervival spine
Study NCT03286322 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: control group
Description: the manuel therapy in physiotherapy is classic and not focused on the cervival spine
Study NCT01551212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: tablet containing 0.25mg, 0.5mg, 0.75mg or 1.0mg
Study NCT01551212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: capsule containing 0.5, 1.0, or 5.0mg
Study NCT01551212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: capsule containing 0.5, 1.0, or 5.0mg
Study NCT01551212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids may have been used for the duration of the study according to the investigator's discretion, but may not have been eliminated sooner than 6 months post-transplantation.